Patent · US Active

DNA expression constructs encoding the Leishmania infantum antigens thiol-specific antioxidant protein and kinetoplastid membrane protein

US8669100B2 · kind B2 · utility

0Cited by

3References

4Claims

0Family size

Assignee

Mologen AG · DE

Inventors

Burghardt Wittig · Berlin, DE
Laura Fuertes-López · Madrid, ES
Marcos Timon-Jimenez · San Lorenzo de El Escorial, ES

Key dates

Filing date	Jul 22, 2010
Grant date	Mar 11, 2014
Priority date	—
Expiry date	Jul 22, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to using a combination of DNA-expression constructs for producing a drug for immunization against leishmania infections and a corresponding vaccine. The DNA-expression construct is also disclosed. According to said invention the immunogene P36 LACK is used in combination with a leishmania infantum thiol-specific antioxidant protein gene (TSA), leishmania infantum kinetoplastid membrane protein 11 (KMP-11) and with a leishmania infantum GP63 antigen for producing an immune response. Plasmides, preferably minimalist immunologically defined gene-expression constructs (MIDGE) can be used in the form of the DNA-expression construct. The inventive DNA-expression construct makes it possible to produce a vaccine for treating leishmania infectious diseases and is used in the form of a component of said vaccine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.